Rebirth of the God-level Xueba

Yang Rui has never made a complete new medicine, it would be too time-consuming and unnecessary.

Few pharmaceutical companies in the world will make and sell a new drug from beginning to end. For the same reason-the payment cycle of up to 20 years is unbearable for normal pharmaceutical companies. What a hundred-year-old store, or a two-hundred-year-old company, if you spend all your time on the development of one type of drug, you can only make a few types in your life, and you have to guard against the failure rate of about six out of seven...

Even super pharmaceutical companies have their own focus, such as the most famous Pfizer, whose strongest ability is sales. Of course, this does not mean that their manufacturing and R\u0026D capabilities are weak. For example, the main ingredient of Viagra, sildenafil, was developed by a subsidiary of Pfizer.

Historically, it took them almost six or seven years to find a suitable active compound, and then five or six years of verification, which perfectly proved that sildenafil was useless in lowering blood pressure...

As for the development of Viagra, it is not so much luck as it is a desperate effort!

For Pfizer, the failure to develop a new drug is an inevitable situation, and several new drugs must fail in a year.

But how many decades are there in the life of a researcher who devotes himself to this?

For the researcher in charge of the project, the investment cost is even higher. He will have to spend at least ten years to accumulate experience, maybe fifteen to twenty years, before he has the opportunity to host such a project. Counting the previous academic investment, if a new drug fails, especially the first new drug presided over in my life, the result will be disastrous.

Being the director of a laboratory is like being the director of a film.

Investors allow you to fail. Some short-term losses, or even long-term small losses, are acceptable. Just like investing 10 million in a movie, 10 million at the box office is not completely unacceptable. Directors who make such films will not be sought after or even welcomed, but they can still find work.

However, if you invest $30 million in new drug research and development and get zero box office results, what do investors think?

Can the researcher in charge of this project find new projects?

Of course, in the development of new drugs, the situation of complete losses is relatively rare.

Especially if you zoom in on the time span, the development of new compounds is the lowest risk—compared to the entire new drug development process.

It is also because of this that Yang Rui started with compounds in the beginning.

It has the lowest requirements for laboratories and researchers. The most important thing is that as long as the cost is well controlled, no matter how bad the compound is, it can be sold for money.

In other words, there are no bad compounds, only medical experts who can't find a use for them. For example, Mevastatin was first discovered by the Japanese Akira Endo. The Sankyo Pharmaceutical team led by Akira Endo spent more than two years screening more than 6,000 different microorganisms to find the compound, and then it took another seven years to complete clinical trials.

However, the Japanese stopped clinical trials around 80 years ago, because the dogs used for animal experiments showed a disturbing increase in the proportion of malignant tumors.

Merck Pharmaceuticals, which screened out similar compounds in 1978, originally wanted to pick up a cheap one, but it didn’t expect this to happen to the compound it just spent a lot of money on. Uneasy to continue the clinical trial, and finally lucky to succeed, opened the sales of the tens of billions of blockbuster lovastatin.

Therefore, although the chances of compounds deceiving people are great, they can still be sold for money.

Buying and selling compounds is also a very common thing in the pharmaceutical industry.

The deferiprone compound made by Yang Rui has achieved a milestone of selling, and now it has earned hundreds of millions of dollars. Although the new drug for Gaucher's disease was handed over to North Pharmaceutical, it was because of Yang Rui's good start that foreign companies such as Zeneca were willing to spend money to participate.

Compounds of sildenafil,

Before 1992, it was neither expensive nor cheap.

Pfizer still has expectations for it: a blood pressure lowering drug, if the effect is good, it will be a proper blockbuster. If the annual sales of 1 billion US dollars, the profit must be at least hundreds of millions of dollars.

It is also for such expectations that Pfizer can endure tens of millions of dollars in annual expenses.

However, when it was proved that sildenafil was clinically ineffective around 1992, its value plummeted.

However, Yang Rui is not qualified to block time.

It is well known in the market that even useless compounds will become expensive in the hands of Pfizer.

If they dragged it back and forth and made them discover something strange, Yang Rui would be dead.

Therefore, Yang Rui made a decision and sent two employees from Sinovel to contact Pfizer.

At the same time, Yang Rui also let out the wind, saying that Huarui Company is preparing to further develop pharmaceutical research and development capabilities...

Comrade Li Zhangzhen of Huarui Company was very happy about this.

As the person in charge of the company, the bigger the company is, the more projects there are, and naturally the stronger the sense of accomplishment.

Compared with simply doing pharmaceutical sales work, the integration of industry, education and research sounds much more handsome.

Comrade Li Zhangzhen's happiness lasted for about a week.

In a blink of an eye, his excitement disappeared from his eyes, and when he met Yang Rui, he was even more frustrated: "Pfizer refused."

"Oh, why?" Yang Rui was not surprised.

"There is no useful reason. They don't want to sell sildenafil yet." Li Zhangzhen said with regret, and then asked, "Do you have any other goals?"

"Pfizer refused so directly?" Yang Rui was more concerned about Li Zhangzhen's attitude, and he obviously gave up completely.

Li Zhangzhen nodded helplessly, and said: "Pfizer said that since it is a compound that Nobel laureate Mr. Yang Rui is optimistic about, they will at least invest more in it."

"Uh..." Yang Rui had thought of the possibility, but it was still a bit embarrassing for someone to say it directly.

"The main reason is that the safety test of sildenafil is very good, and Pfizer still has some fantasies about it." Li Zhangzhen sighed.

Yang Rui said indifferently: "Antihypertensive drugs are commonly used drugs, and patients have to take them every day. There is a lot of competition in the market, and the safety is not good, so there is no value in development."

"But it's not easy to find a compound with good safety." Li Zhangzhen said regretfully: "Pfizer didn't raise the price, so it should be completely uninterested."

"En..." Yang Rui pondered slightly.

"Actually, I found out that there are many good antihypertensive compounds on the market. It may be easier to buy from small companies..."

"Since it's not a matter of price, let's look for breakthroughs from other angles." Yang Rui didn't answer Li Zhangzhen's complaints at all, and said to himself: "You ask them to consult with Pfizer, just say... market for technology Bar."

"Market? What market?" Li Zhangzhen still hadn't come to his senses.

"Of course it's the Chinese market." Yang Rui said with the attitude of a GMP committee leader: "You just tell them that if they don't want to talk to us, there is no need to talk about Pfizer's new drugs if they want to enter the Chinese market. .”

There should be BGM here!

...